All News Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
3.85 ^USD	-1.28%		+4.90%	+26.29%

03/05	Aileron Therapeutics Closes Direct Offering of Shares, Warrants	MT
01/05	Transcript : Aileron Therapeutics, Inc. - Special Call

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	16/05	AQ
Aileron Therapeutics to Present at Two Upcoming Investor Conferences	07/05	AQ
Aileron Therapeutics Closes Direct Offering of Shares, Warrants	04/05	MT
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million	04/05	AQ
Transcript : Aileron Therapeutics, Inc. - Special Call	01/05
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million	01/05	AQ
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)	01/05	AQ
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	01/05	CI
Ladenburg Thalmann Adjusts Aileron Therapeutics Price Target to $19 From $9, Maintains Buy Rating	18/04	MT
Aileron Therapeutics : Corporate Presentation April 2024	16/04	PU
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	16/04	AQ
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	16/04	CI
Aileron Therapeutics : Management Change/Compensation - Form 8-K	29/03	PU
Aileron Therapeutics, Inc. Announces CFO Changes	29/03	CI
Aileron Therapeutics, Inc. Announces Board Changes	29/03	CI
Aileron Therapeutics Names Brian Windsor as CEO	12/03	MT
Aileron Therapeutics Announces CEO Transition	12/03	AQ
Aileron Therapeutics, Inc. Announces Appointment of Brian Windsor as President and to the Board of Directors	12/03	CI
Aileron Therapeutics, Inc. Announces CEO Changes	12/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

All News

Filters